FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019

This retrospective review assesses the frequency of surrogate measures used for the first time vs subsequent times in a cancer setting and the surrogate’s strength of correlation with patient-centered outcomes.

Detalles Bibliográficos
Autores principales: Chen, Emerson Y., Haslam, Alyson, Prasad, Vinay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186918/
https://www.ncbi.nlm.nih.gov/pubmed/32338703
http://dx.doi.org/10.1001/jamainternmed.2020.1097
_version_ 1783527057562533888
author Chen, Emerson Y.
Haslam, Alyson
Prasad, Vinay
author_facet Chen, Emerson Y.
Haslam, Alyson
Prasad, Vinay
author_sort Chen, Emerson Y.
collection PubMed
description This retrospective review assesses the frequency of surrogate measures used for the first time vs subsequent times in a cancer setting and the surrogate’s strength of correlation with patient-centered outcomes.
format Online
Article
Text
id pubmed-7186918
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-71869182020-04-30 FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019 Chen, Emerson Y. Haslam, Alyson Prasad, Vinay JAMA Intern Med Research Letter This retrospective review assesses the frequency of surrogate measures used for the first time vs subsequent times in a cancer setting and the surrogate’s strength of correlation with patient-centered outcomes. American Medical Association 2020-06 2020-04-27 /pmc/articles/PMC7186918/ /pubmed/32338703 http://dx.doi.org/10.1001/jamainternmed.2020.1097 Text en Copyright 2020 Chen EY et al. JAMA Internal Medicine. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Research Letter
Chen, Emerson Y.
Haslam, Alyson
Prasad, Vinay
FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019
title FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019
title_full FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019
title_fullStr FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019
title_full_unstemmed FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019
title_short FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019
title_sort fda acceptance of surrogate end points for cancer drug approval: 1992-2019
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186918/
https://www.ncbi.nlm.nih.gov/pubmed/32338703
http://dx.doi.org/10.1001/jamainternmed.2020.1097
work_keys_str_mv AT chenemersony fdaacceptanceofsurrogateendpointsforcancerdrugapproval19922019
AT haslamalyson fdaacceptanceofsurrogateendpointsforcancerdrugapproval19922019
AT prasadvinay fdaacceptanceofsurrogateendpointsforcancerdrugapproval19922019

Ejemplares similares